Keyphrases
Down Syndrome
100%
Clinical Effect
100%
Myeloid Neoplasms
100%
Driver mutations
100%
Transient Abnormal Myelopoiesis
17%
ZBTB7A
11%
Tumor Protein p53 (TP53)
5%
Poor Prognosis
5%
Event-free Survival
5%
New Therapeutic Strategies
5%
Common Complications
5%
Poor Outcome
5%
Janus Kinase 2 (JAK2)
5%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
5%
Favorable Prognosis
5%
Exome Sequencing
5%
TP53 mutation
5%
Refractoriness
5%
Acute Myeloid Leukemia
5%
New Drug Targets
5%
Spontaneous Regression
5%
Pediatric Leukemia
5%
Relapsed or Refractory
5%
Genomic Profiling
5%
Bromodomain-containing Protein 4 (BRD4)
5%
Chromosome 21
5%
Acute Megakaryoblastic Leukemia
5%
Runt-related Transcription Factor 1 (RUNX1)
5%
Myeloid Leukemia
5%
Tandem Duplication
5%
CDKN2A Deletion
5%
Mutational Target
5%
MYC Pathway
5%
Leukemia Progression
5%
Pediatric Lymphoma
5%
IRX1
5%
Mutational Landscape
5%
Medicine and Dentistry
Neoplasm
100%
Down Syndrome
100%
Myelopoiesis
18%
Leukemia
12%
Myeloid Leukemia
6%
Event Free Survival
6%
Pediatrics
6%
Exome Sequencing
6%
Upregulation
6%
Neonatal Infant
6%
Acute Myeloid Leukemia
6%
Spontaneous Remission
6%
Janus Kinase
6%
Patient with Down Syndrome
6%
Acute Megakaryoblastic Leukemia
6%
Chromosome 21
6%
Biochemistry, Genetics and Molecular Biology
Down Syndrome
100%
Myeloid
100%
Myelopoiesis
17%
Upregulation
5%
Event Free Survival
5%
Exome Sequencing
5%
Janus Kinase
5%
Bromodomain
5%
Chromosome 21
5%
RUNX1
5%
Genomics
5%